The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Affiliation
Comparative Outcomes Group
Country
United Kingdom
Current Status, Position
Dr Paul Cornes is an Oncologist from the UK and a full-time Cancer Researcher with the Comparative Outcomes Group. He was the plenary lecturer on Value and Economics for the last meeting of the Gastrointestinal Cancer Group of the European Society of Medical Oncology. He was in the steering group for the European School of Oncology programme on Access to Innovation in Cancer Treatment. His most recent book is “Fast Facts – Biosimilars in Haematology and Oncology” – co-written with Ali McBride, a US Hospital Pharmacist from Tucson, AZ.
Education
Dr Paul Cornes trained in medicine at Oxford University and in oncology at the Royal Marsden Hospital, London before taking a Consultant Post at Bristol & Bath, UK. He is currently part of the Cochrane Collaboration.
Research Area
Dr Paul Cornes has a special interest in health economics, affordable healthcare policy & practice. He has been on the expert panel for two biosimilar approvals at the FDA, and is a stakeholder with the European Commission Biosimilars Group and has written two recent books on the subject: fast facts, biosimilars and biosimilars in haematology and oncology.
Conflict of interest:
Dr Paul Cornes is on the advisory boards of Accord Healthcare. He also currently is on the advisory board and received speaker fees from Mylan-Biocon, Sandoz and Pfizer.
The European Comission covers for his travel expenses to attend meetings.